ABVXABIVAX Société Anonyme
$88.00-5.3% 1Y
$88.00
$72.5052 weeks$145.31
Is the business good?
How good a business is ABVX?
ABIVAX Société Anonyme spent more than it took in: an operating loss of $246M on $5.6M of revenue, 12 months to Q4 2025.
$246M
Operating loss · on $5.6M of revenue · 12 months to Q4 2025
| Year | Operating margin |
|---|---|
| FY2021 | −346% |
| FY2022 | −1415% |
| FY2023 | −2756% |
| FY2024 | −1390% |
| FY2025 | −4394% |
Details›
- Operating margin12 months to Q4 2025
- −4394%
- Net margin12 months to Q4 2025
- −6002%
- Free cash flow margin
- −2880%
- R&D as % of revenue
- 3174%
- Revenue, trailing twelve months
- $5.6M
- Free cash flow, trailing twelve months
- −$161M
- Net income, trailing twelve months
- −$336M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.